Programme
View the 2019 Scientific Programme
08:00
E2
Session starts at 08:00
E2
Session starts at 08:00
WG2.1
08:24
E2
Session starts at 08:00
E2
Session starts at 08:00
WG2.2
EU vs. non-EU practices on Insulin Resistance assessment (ESPE ObWG project)
Tetyana Chaychenko
(Kharkiv, Ukraine)
08:48
E2
Session starts at 08:00
E2
Session starts at 08:00
WG2.3
Insulin function in obese children within the low and high ranges of impaired fasting glycemia
Claude Marcus
(Solna, Sweden)
09:12
E2
Session starts at 08:00
E2
Session starts at 08:00
WG2.4
09:36
E2
Session starts at 08:00
E2
Session starts at 08:00
WG2.5
08:05
E1
Session starts at 08:00
E1
Session starts at 08:00
WG1.1
08:45
E1
Session starts at 08:00
E1
Session starts at 08:00
WG1.3
09:05
E1
Session starts at 08:00
E1
Session starts at 08:00
WG1.4
09:25
E1
Session starts at 08:00
E1
Session starts at 08:00
WG1.5
09:35
E1
Session starts at 08:00
E1
Session starts at 08:00
WG1.6
08:30
F1
Session starts at 08:00
F1
Session starts at 08:00
WG3.3
Mechanisms of vascular calcification and potential treatment implications
Frank Rutsch
(Münster, Germany)
09:25
F1
Session starts at 08:00
F1
Session starts at 08:00
WG3.6
08:05
F2
Session starts at 08:00
F2
Session starts at 08:00
WG4.1
08:25
F2
Session starts at 08:00
F2
Session starts at 08:00
WG4.2
08:45
F2
Session starts at 08:00
F2
Session starts at 08:00
WG4.3
09:20
F2
Session starts at 08:00
F2
Session starts at 08:00
WG4.5
Time in Range (TIR) - Highlights from the consensus meeting February 2019
Tadej Battelino
(Ljubljana, Slovenia)
09:40
F2
Session starts at 08:00
F2
Session starts at 08:00
WG4.6
08:00
HALL B
Session starts at 08:00
HALL B
Session starts at 08:00
WG5.1
08:23
HALL B
Session starts at 08:00
HALL B
Session starts at 08:00
WG5.2
08:46
HALL B
Session starts at 08:00
HALL B
Session starts at 08:00
WG5.3
09:09
HALL B
Session starts at 08:00
HALL B
Session starts at 08:00
WG5.4
09:32
HALL B
Session starts at 08:00
HALL B
Session starts at 08:00
WG5.5
08:00
HALL C
Session starts at 08:00
HALL C
Session starts at 08:00
WG6.1
Assessing competence to consent to physical treatment in transgender adolescents
Annelou De Vries
(Amsterdam, The Netherlands)
08:30
HALL C
Session starts at 08:00
HALL C
Session starts at 08:00
WG6.2
09:00
HALL C
Session starts at 08:00
HALL C
Session starts at 08:00
WG6.3
08:20
HALL A
Session starts at 08:00
HALL A
Session starts at 08:00
WG7.2
08:40
HALL A
Session starts at 08:00
HALL A
Session starts at 08:00
WG7.3
Endocrine management of Turner Sydndrome in adolescents and early adulthood
Melanie Davis
(London, United Kingdom)
09:05
HALL A
Session starts at 08:00
HALL A
Session starts at 08:00
WG7.4
09:30
HALL A
Session starts at 08:00
HALL A
Session starts at 08:00
WG7.5
Cardiac morbidity and mortality during pregnancy in TS
Anthonie Duijnhouwers
(Nijmegen, The Netherlands)
HALL A
Session starts at 10:45
PL1
HALL B
Session starts at 12:00
S1.1
HALL B
Session starts at 12:00
S1.3
New developments for treatments in monogenic disorders focusing on setmelanotide trials
Christine Poitou
(Paris, France)
E1
Session starts at 12:00
S2.1
Longitudinal bone growth: fundamental mechanisms to clinical applications
Jeffrey Baron
(Bethesda, USA)
E1
Session starts at 12:00
S2.2
E1
Session starts at 12:00
S2.3
HALL A
Session starts at 12:00
S3.1
HALL A
Session starts at 12:00
S3.2
HALL A
Session starts at 12:00
S3.3
HALL C
Session starts at 12:00
S4.1
HALL C
Session starts at 12:00
S4.2
HALL C
Session starts at 12:00
S4.3
Prediction of renal and cardiovascular complications
Loredana Marcovecchio
(Cambridge, United Kingdom)
E2
Session starts at 12:00
ACT1.1
Online learning project for Resource Limited Countries (RLC) Introduction
Annemieke Boot
(Groningen, The Netherlands)
E2
Session starts at 12:00
ACT1.2
14:45
E1
Session starts at 14:45
E1
Session starts at 14:45
RFC1.1
Low prevalence of maternal microchimerism in Japanese children with type 1 diabetes
Kikumi Ushijima
(Tokyo, Japan)
14:50
E1
Session starts at 14:45
E1
Session starts at 14:45
RFC1.2
Gabra5 contributes to sexual dimorphism in POMC neural activity and glucose metabolism
Zhou Pei
(Shanghai, China)
14:55
E1
Session starts at 14:45
E1
Session starts at 14:45
RFC1.3
The association between IGF-1 levels and nonalcoholic fatty liver disease (NAFLD) in adolescents with type 2 diabetes
Jose Antonio Orozco Morales
(Mexico City, Mexico)
15:00
E1
Session starts at 14:45
E1
Session starts at 14:45
RFC1.4
Estimation of MODY frequency and prevalent subtypes in pediatric patients by targeted NGS
Luis Salamanca
(Madrid, Spain)
15:05
E1
Session starts at 14:45
E1
Session starts at 14:45
RFC1.5
Decreased circulating levels of MOTS-c in individuals with newly diagnosed type 1 diabetes children
Caiqi Du
(Wuhan, China)
15:10
E1
Session starts at 14:45
E1
Session starts at 14:45
RFC1.6
An oral trace element supplementation has a potential beneficial effect on glucose homeostasis in transfused patients with β-thalassemia major complicated with diabetes mellitus
Nancy Elbarbary
(Cairo, Egypt)
15:15
E1
Session starts at 14:45
E1
Session starts at 14:45
FC1.1
15:25
E1
Session starts at 14:45
E1
Session starts at 14:45
FC1.2
Three new genes (PTPRD, SYT9, and WSF1) related to Korean maturity-onset diabetes in the young (MODY) children decrease insulin synthesis and secretion in human pancreatic beta cells
Kyung-Mi Jang
(Daegu, Republic of Korea)
15:35
E1
Session starts at 14:45
E1
Session starts at 14:45
FC1.3
Next generation sequencing in Greek MODY patients increases diagnostic accuracy and reveals a high percentage of MODY12 cases
Amalia Sertedaki
(Athens, Greece)
15:55
E1
Session starts at 14:45
E1
Session starts at 14:45
FC1.5
FADES: A birth cohort to understand the mechanisms underlying accelerated onset of autoimmunity in children with Down’s syndrome
Georgina Williams
(Chippenham, United Kingdom)
16:05
E1
Session starts at 14:45
E1
Session starts at 14:45
FC1.6
A novel biochemical marker, fatty acid-binding protein 4, in diabetic ketoacidosis in children
Noah Gruber
(Ramat Gan, Israel)
HALL B
Session starts at 14:45
MTE1.1
HALL C
Session starts at 14:45
MTE2.1
The interpretation of abnormal thyroid function tests in children and adolescents
Carla Moran
(Cambridge, United Kingdom)
14:45
HALL A
Session starts at 14:45
HALL A
Session starts at 14:45
HDI1.1
15:15
HALL A
Session starts at 14:45
HALL A
Session starts at 14:45
HDI1.2
How Do I... Manage a patient with Prader Willi and GH at transition - do they benefit as adults?
Maithé Tauber
(Toulouse, France)
15:45
HALL A
Session starts at 14:45
HALL A
Session starts at 14:45
HDI1.3
14:45
E2
Session starts at 14:45
E2
Session starts at 14:45
RFC2.1
Burosumab resulted in better clinical outcomes than continuation with conventional therapy in both younger (1-4 years-old) and older (5-12 years-old) children with X-linked hypophosphatemia
Wolfgang Högler
(Linz, Austria)
14:50
E2
Session starts at 14:45
E2
Session starts at 14:45
RFC2.2
Does the treatment with recombinant human growth hormone improve final height in patients affected by X-linked hypophosphatemia?
Julia André
(Le Kremlin Bicêtre, France)
14:55
E2
Session starts at 14:45
E2
Session starts at 14:45
RFC2.3
Growth hormone effects on metacarpal bone geometry and bone age in growth hormone-deficient children
David D Martin
(Tübingen, Germany)
15:00
E2
Session starts at 14:45
E2
Session starts at 14:45
RFC2.4
Bone mass and fracture prevalence in childhood brain cancer survivors 2, 5 or 7 years after off therapy
Annalisa Gallizia
(Genova, Italy)
15:05
E2
Session starts at 14:45
E2
Session starts at 14:45
RFC2.5
Long term effects of treatment with oxandrolone (Ox) in addition to growth hormone (GH) in girls with Turner syndrome (TS) on bone mineral density in adulthood
Theo Sas
(Rotterdam, The Netherlands)
15:10
E2
Session starts at 14:45
E2
Session starts at 14:45
RFC2.6
Impact of pubertal suppression on body composition and bone mineral density in adolescents with gender dysphoria
Andreas Kyriakou
(Glasgow, United Kingdom)
15:15
E2
Session starts at 14:45
E2
Session starts at 14:45
FC2.1
Continued improvement in clinical outcomes with burosumab, a fully human anti-FGF23 monoclonal antibody: results from a 3-year, phase 2, clinical trial in children with X-linked hypophosphatemia (XLH)
Agnès Linglart
(Le Kremlin-Bicêtre, France)
15:25
E2
Session starts at 14:45
E2
Session starts at 14:45
FC2.2
Benefits of long-term burosumab persist in 11 girls with X-linked hypophosphatemia (XLH) who transitioned into adolescence during the phase 2 CL201 trial
Annemieke Boot
(Groningen, The Netherlands)
15:35
E2
Session starts at 14:45
E2
Session starts at 14:45
FC2.3
Higher dose of burosumab is needed for treatment of children with severe forms of X linked hypophosphatemia
Volha Zhukouskaya
(Le Kremlin-Bicêtre, France)
15:45
E2
Session starts at 14:45
E2
Session starts at 14:45
FC2.4
New imaging approaches to the quantification of musculoskeletal alterations in X-linked hypophosphatemic rickets (XLH)
Adalbert Raimann
(Vienna, Austria)
15:55
E2
Session starts at 14:45
E2
Session starts at 14:45
FC2.5
Age and gender-specific reference data for high-resolution magnetic resonance based musculoskeletal parameters in healthy children and young people
Huda M Elsharkasi
(Glasgow, United Kingdom)
16:05
E2
Session starts at 14:45
E2
Session starts at 14:45
FC2.6
Validation of a new version of BoneXpert bone age in children with congenital adrenal hyperplasia (CAH), precocious puberty (PP), growth hormone deficiency (GHD), Turner syndrome (TS), and other short stature diagnoses
David D Martin
(Tübingen, Germany)
14:45
F1
Session starts at 14:45
F1
Session starts at 14:45
RFC3.1
European Registries For Rare Endocrine Conditions (EuRRECa): results from the pilot phase of The Platform For e-Reporting Of Rare Endocrine Conditions (e-REC)
Salma Ali
(Glasgow, United Kingdom)
14:50
F1
Session starts at 14:45
F1
Session starts at 14:45
RFC3.2
Factors affecting loss to follow-up for patients with chronic endocrine conditions during the pediatric period: a cohort study at a reference center for rare diseases
Laura Atger-Lallier
(Paris, France)
14:55
F1
Session starts at 14:45
F1
Session starts at 14:45
RFC3.3
The founder homozygous NR5A1 gene mutation p.R103Q causes asplenia and severe XY-DSD and XX-DSD in a Palestinian cohort
Maha Abdulhadi-Atwan
(Hebron, Palestine)
15:00
F1
Session starts at 14:45
F1
Session starts at 14:45
RFC3.4
Peripheral glucocorticoid metabolism may reflect resolution of inflammation in Kawasaki disease
Shuji Sai
(Sapporo, Japan)
15:05
F1
Session starts at 14:45
F1
Session starts at 14:45
RFC3.5
Evaluation of endothelial function in childhood standard risk acute lymphoblastic leukemia survivors: role of subclinical markers and identification of preventable factors
Patrizia Bruzzi
(Modena, Italy)
15:10
F1
Session starts at 14:45
F1
Session starts at 14:45
RFC3.6
Prevalence of endocrine complications in Duchenne muscular dystrophy
Primož Kotnik
(Ljubljana, Slovenia)
15:15
F1
Session starts at 14:45
F1
Session starts at 14:45
FC3.1
Germline-derived gain-of-function variants of Gsα-coding GNAS gene identified in nephrogenic syndrome of inappropriate antidiuresis: the first report
Maki Fukami
(Tokyo, Japan)
15:25
F1
Session starts at 14:45
F1
Session starts at 14:45
FC3.2
CFTR loss-of-function has effects on microRNAs (miRNAs) that regulate genes involved in growth, glucose metabolism and in fertility in in vitro models of cystic fibrosis
Francesca Cirillo
(Reggio Emilia, Italy)
15:35
F1
Session starts at 14:45
F1
Session starts at 14:45
FC3.3
Variability in drug metabolizing cytochrome P450 activities caused by human genetic variations in NADPH cytochrome P450 oxidoreductase (POR)
Maria Natalia Rojas Velazquez
(Bern, Switzerland)
15:45
F1
Session starts at 14:45
F1
Session starts at 14:45
FC3.4
Droplet digital PCR is a useful method for detection of mosaic mutations in patients with McCune–Albright syndrome
Satoshi Watanabe
(Nagasaki, Japan)
15:55
F1
Session starts at 14:45
F1
Session starts at 14:45
FC3.5
Evaluation of endocrine late effects in survivors of childhood allogeneic hematopoietic stem cell transplantation in Australia database from 1985 to 2011
Samantha Lai-Ka Lee
(Melbourne, Australia)
16:05
F1
Session starts at 14:45
F1
Session starts at 14:45
FC3.6
Severe infections contribute to increased risk of early death in patients with apeced
Joonatan Borchers
(Helsinki, Finland)
HALL A
Session starts at 16:30
PL2
17:00
E1
Session starts at 17:00
E1
Session starts at 17:00
RFC4.1
Expression of miRNAs in circulating exosomes derived from patients with NAFLD
Junfen Fu
(Zhejiang, China)
17:05
E1
Session starts at 17:00
E1
Session starts at 17:00
RFC4.2
Circulating exosomal miRNAs in children’s nonalcoholic steatohepatitis and the correlation with serum transaminase and uric acid
Xuelian Zhou
(Hangzhou, China)
17:10
E1
Session starts at 17:00
E1
Session starts at 17:00
RFC4.3
Dysregulated gene expression profile in visceral adipose tissue of juvenile Wistar rats with catch-up growth: association with fat expansion and metabolic parameters
Judit Bassols
(Salt, Spain)
17:15
E1
Session starts at 17:00
E1
Session starts at 17:00
RFC4.4
The novel phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib effectively inhibits growth of PTEN haploinsufficient lipoma cells
Anna Kirstein
(Leipzig, Germany)
17:20
E1
Session starts at 17:00
E1
Session starts at 17:00
RFC4.5
GDF5 increased white adipose tissue thermogenesis through p38 MAPK signaling pathway in fatty acid-binding protein 4-GDF5 transgenic mice
Feihong Luo
(Shanghai, China)
17:25
E1
Session starts at 17:00
E1
Session starts at 17:00
RFC4.6
Appetite suppressing effects of glucoregulatory peptides devoid of nausea
Christian L Roth
(Seattle, USA)
17:30
E1
Session starts at 17:00
E1
Session starts at 17:00
FC4.1
Involvement of visfatin in adipose tissue fibrosis through modulation of extracellular matrix proteins
Mitra Nourbakhsh
(Tehran, Islamic Republic of Iran)
17:40
E1
Session starts at 17:00
E1
Session starts at 17:00
FC4.2
Characterization of the adipose progenitor cell marker MSCA1 in normal weight and obese children
Martha Hanschkow
(Leipzig, Germany)
17:50
E1
Session starts at 17:00
E1
Session starts at 17:00
FC4.3
Circulating growth-and-differentiation factor-15 in early life: relation to prenatal and postnatal size
Marta Díaz
(Barcelona, Spain)
18:00
E1
Session starts at 17:00
E1
Session starts at 17:00
FC4.4
The rs72613567:TA variant in the hydroxysteroid 17-beta dehydrogenase 13 gene reduces liver damage in obese children
Anna Di Sessa
(Naples, Italy)
18:10
E1
Session starts at 17:00
E1
Session starts at 17:00
FC4.5
18:30
E1
Session starts at 17:00
E1
Session starts at 17:00
FC4.6
Brain satiety responses to a meal in children before and after weight management intervention
Christian L Roth
(Seattle, USA)
HALL B
Session starts at 17:00
MTE3.1
Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting
Claus Højbjerg Gravholt
(Aarhus, Denmark)
HALL C
Session starts at 17:00
MTE4.1
17:36
HALL A
Session starts at 17:00
HALL A
Session starts at 17:00
17:00
E2
Session starts at 17:00
E2
Session starts at 17:00
RFC5.1
Hurthle cell carcinoma in childhood retrospective analysis of a large series
Giorgia Pepe
(Messina, Italy)
17:05
E2
Session starts at 17:00
E2
Session starts at 17:00
RFC5.2
17:10
E2
Session starts at 17:00
E2
Session starts at 17:00
RFC5.3
Experience of thyroid surgery in children with intraoperative neuromonitoring
Alexander Anikiev
(Moscow, Russian Federation)
17:15
E2
Session starts at 17:00
E2
Session starts at 17:00
RFC5.4
Thyroid dysfunction in patients following thymus transplantation in a tertiary centre: a 10-year experience
Sommayya Aftab
(London, United Kingdom)
17:20
E2
Session starts at 17:00
E2
Session starts at 17:00
RFC5.5
A novel mutation in the thyroglobulin gene leading to neonatal goiter and congenital hypothyroidism in an Eritrean infant
Eve Stern
(Ramat Gan, Israel)
17:25
E2
Session starts at 17:00
E2
Session starts at 17:00
RFC5.6
Complex single nucleotide polymorphisms in SEPINA 7 lead to TBG deficiency
Fang Yanlan
(Hangzhou, China)
17:30
E2
Session starts at 17:00
E2
Session starts at 17:00
FC5.1
Randomised trial of block and replace versus dose titration antithyroid drug treatment in children and adolescents with thyrotoxicosis
Claire Wood
(Newcastle upon Tyne, United Kingdom)
17:40
E2
Session starts at 17:00
E2
Session starts at 17:00
FC5.2
Lower proportion of CD19+IL-10+ and CD19+CD24hiCD27+ IL-10+, but not CD1d+CD5+CD19+CD24+CD27+ IL-10+ B cells in children with autoimmune thyroid diseases
Karolina Stożek
(Bialystok, Poland)
17:50
E2
Session starts at 17:00
E2
Session starts at 17:00
FC5.3
Predominant DICER1 mutations in pediatric follicular thyroid carcinomas
Young Ah Lee
(Seoul, Republic of Korea)
18:00
E2
Session starts at 17:00
E2
Session starts at 17:00
FC5.4
Thyroid dysgenesis: exome-wide analysis identifies rare variants in genes involved in thyroid development and cancer
Stéphanie Larrivée-Vanier
(Montreal, Canada)
18:10
E2
Session starts at 17:00
E2
Session starts at 17:00
FC5.5
Identification of TRPC4AP as a novel candidate gene causing thyroid dysgenesis
Daniela Choukair
(Heidelberg, Germany)
18:20
E2
Session starts at 17:00
E2
Session starts at 17:00
FC5.6
Homozygous loss-of-function mutation in the SLC26A7 gene coding a novel iodide transporter causes goitrous congenital hypothyroidism
Atsushi Suzuki
(Nagoya, Japan)